Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Carcinoma, Merkel Cell × pembrolizumab × Clear all

Phase

Status

Recruiting 9 Terminated 7 Active not recruiting 5 Completed 3 Unknown 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 10 Triple Negative Breast Neoplasms 7 Squamous Cell Carcinoma of Head and Neck 7 Head and Neck Neoplasms 5 Turcot syndrome 3 Prostatic Neoplasms 3 Neoplasm Metastasis 3 Lung Neoplasms 3 Carcinoma, Renal Cell 3 Breast Neoplasms 3 Uterine Cervical Neoplasms 2 Hodgkin Disease 2 Glioblastoma 2 Colorectal Neoplasms 2 Colonic Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Hepatocellular 2 Biliary Tract Neoplasms 2 Advanced Endometrial Cancer 2 Vulvar Neoplasms 1 To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma 1 Thyroid Neoplasms 1 Thoracic Neoplasms 1 Stomach Neoplasms 1 Squamous NSCLC 1 Solid Tumors 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Rare Tumour 1 Primary Glioblastoma 1

Interventions

pembrolizumab 1 decitabine and cedazuridine drug combination 1 cemiplimab 1 Etoposide 1 Cisplatin 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06086288 2023-10-17

PANDORA

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Not yet recruiting

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡